Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP), a global
biopharmaceutical company, today announced that it has received orphan
drug designation in the European Union for unoprostone isopropyl for the
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda
Pharmaceuticals U.S.A., Inc. (TPUSA) announced today that the United
States (U.S.) Food and Drug Administration (FDA) has approved Sucampo's
supplemental new drug...
In a report published Wednesday, Cantor Fitzgerald analyst Irina Rivkind initiated coverage on Sucampo Pharmaceuticals (NASDAQ: SCMP) with a Buy rating and $9.00 price target.
In the report, Rivkind noted, “Sucampo is a closely held...
Sucampo Pharmaceuticals (SCMP) announced that earnings increased to $13.5 million, or 32 cents per share, up from $2.7 million, or 6 cents per share. Revenue increased to $34.9 million from $14.2 million, while research and development revenue...
Sucampo Pharmaceuticals (NASDAQ: SCMP) (SPI) today announced that RESCULA (unoprostone
isopropyl ophthalmic solution) 0.15% is now available by prescription
across the United States. The U.S. Food and Drug Administration (FDA)
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Sucampo Pharmaceuticals (SCMP):